Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types

Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and... | November 7, 2022

Related Keywords

United States ,United Kingdom ,Montefiore ,Lazio ,Italy ,Washington ,Groningen ,Netherlands ,Boston ,Massachusetts ,Austria ,Northern Ireland ,Craigavon ,London ,City Of ,Germany ,Gothenburg ,Vastra Gotalands Lan ,Sweden ,Belgium ,America ,Scotland ,Henkjanj Verkade ,Colleen Alabiso ,Erik Lindstr ,Lorenzo Dantiga ,Lance Buckley ,Mark Nomden ,Richard Thompson ,Richardj Thompson ,Hans Vitzthum ,Jan Mattsson ,Nadia Ovchinsky ,Intrahepatic Cholestasis ,Azienda Ospedaliera Papa Giovanni ,Asia Pacific ,Georg Friedrich Vogel ,King College London ,Department Of Paediatric Hepatology ,Nasdaq ,Astrazeneca ,University Of Groningen ,Globenewswire Inc ,Albireo Pharma Inc ,Lifesci Advisors ,Hospital University Medical Centre Groningen ,Department Of Paediatrics ,Albert Einstein College Of Medicine ,European Commission ,Interest Group ,University Medical Center Groningen ,Department Of Surgery ,Institute Of Liver ,Regulatory Agency ,Exchange Commission ,American Association ,Liver Diseases ,Pediatric Hepatology ,Chief Scientific Officer ,Molecular Hepatology ,College London ,Liver Meeting ,Sustained Effects ,Late Breaking Parallel Session Presentation ,Alagille Syndrome ,Top Line Results ,Einstein College ,Late Breaking Oral Abstract Session ,Native Liver Survival ,Odevixibat Serum Bile Acid Responders ,Progressive Familial Intrahepatic ,Liver Studies ,Pediatric Liver Disease ,Odevixibat Treatment ,Responsive Patients ,Serum Bile Acid ,Medical Center Groningen ,Improvement Across Wide Range ,Long Term Efficacy ,Progressive Familial Intrahepatic Cholestasis ,Poster Session ,Serum Bile Acid Levels ,Pruritus Scores ,Growth Over Time ,Odevixibat Responders ,Pooled Data ,Lorenzod Antiga ,Paediatric Hepatology ,Beatrix Children ,University Medical Centre Groningen ,Odevixibat Therapy ,Retrospective Case ,Friedrich Vogel ,Assistant Professor ,Medical University ,Recurrent Episodic Cholestasis ,Biallelic Mutations ,Angelo Di Giorgio ,Hospital Papa Giovanni ,Cholestatic Liver ,Autoimmune Liver Diseases ,Urinary Excretion ,Bile Acids ,Halts Liver Disease Progression ,North America ,Middle East ,Kingdom Medicines ,Test Abnormalities ,Soluble Vitamin ,Open Label Extension ,Private Securities Litigation Reform Act ,Annual Report ,Albireo Pharma ,Nc Stock Exchange ,News ,Information ,Press Release ,End ,Sustained ,Efficacy ,Cross ,Tide ,Orange ,F ,Patients ,Ith ,Evidence ,Disease ,Reservation ,Native ,Liver ,N ,Improvements ,Ile Albo Us01345p1066 ,